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The human polyomavirus JC (JCPyV) is the causative agent of progressive multifocal 
leukoencephalopathy (PML), a demyelinating disease of the brain. Although archetype JCPyV 
exists as an asymptomatic infection in the healthy population, PML occurs almost exclusively in 
individuals with immunodeficiencies or on immunomodulatory medication. When immune function 
is perturbed, the mechanisms which maintain viral latency are disrupted and can lead to the 
development of PML. Therefore, an important question in understanding PML pathogenesis are 
the molecular mechanisms which maintain JCPyV latency. The JCPyV genome incorporates 
host-derived histones and closely resembles host chromatin structure, therefore we hypothesize 
it is subject to epigenetic regulation. Histone deacetylase inhibitors (HDACi) have been 
demonstrated to increase rearranged JCPyV replication in a transfection model and are 
candidates for latency reversal agents in HIV treatment. The potential for these HDACi to 
reactivate HIV suggests the possibility of reactivating other viruses as well. The objective of this 
study is to characterize the effects of histone deacetylase inhibitors (HDACis) on archetype 
JCPyV infection, replication, and rearrangement in vitro and in vivo. Here, we demonstrate that 
HDACi, Trichostatin A, treatment of primary human brain cortical astrocytes and renal proximal 
tubule epithelial cells increases both early and late archetype JCPyV replication in a cell-specific 
manner. Further, we demonstrate in patients treated with HDACi, panobinostat, statistically higher 
increase in archetype JCPyV genome copy number in urine, which was abrogated after treatment. 
To our knowledge, this is the first study to show the effect of HDACi on archetype JCPyV 
replication in an in vitro infection model and the first to investigate JCPyV viruria during HDACi 
treatment. Taken together, these findings suggest that HDACi modulate archetype JCPyV 
replication. This study emphasizes the need to understand the effects of these global HDACi on 
other viruses to improve risk stratification for latency reactivation agent treatments. These findings 
will open new therapeutic strategies for treatment of PML aimed at preventing viral replication and 
maintaining JCPyV in a latent state.   
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Progressive multifocal leukoencephalopathy (PML) is a subacute demyelinating disease 
of the central nervous system (CNS) caused by the ubiquitous human polyomavirus JC (JCPyV). 
The onset of PML is insidious, typically presenting with neuropsychological deficits. The natural 
disease progression is usually rapid with death occurring 3 to 6 months after diagnosis. The 
neuropathological hallmarks of PML consist of multifocal microscopic and macroscopic 
demyelinating lesions typically in the subcortical white matter near the gray-white matter junction. 
Ultrastructural examination reveals nuclei of infected oligodendrocytes packed with electron-
dense JCPyV particles, measuring approximately 40 nm in diameter (4). PML was originally 
recognized as a rare complication of hematological malignancies or systemic inflammatory 
disorders, however, a dramatic 50-fold increase in the incidence during the past 30 years occurred 
as a result of the acquired immunodeficiency syndrome (AIDS) epidemic (5). AIDS is the most 
frequent condition associated with PML (6), with approximately 6% of patients developing AIDS-
related PML (7). A resurgence of PML occurred in the 2000s as a result of the use of 
immunomodulatory compounds, including monoclonal antibodies natalizumab, efalizumab, and 
rituximab, for the treatment of the autoimmune conditions, such as multiple sclerosis, Crohn’s 
disease, severe forms of plaque psoriasis, hematologic malignancies, and rheumatoid arthritis 









Figure 1. Phylogenetic tree of Polyomaviridae. Based on whole genome sequencing, the 
members of the Polyomaviridae family have been classified into four distinct genera: 
Alphapolyomavirus with members Merkel cell polyomavirus (MCPyV) and Trichodysplasia 
spinulosa-associated polyomavirus (TSPyV); Betapolyomavirus with notable human viruses, BK 
polyomavirus (BKPyV), JC polyomavirus (JCPyV), Deltapolyomavirus containing orphan human 
viruses, including human polyomavirus 6 (HPyV6) and 7 (HPyV7); and Gammapolyomavirus 





JCPyV is a neurotropic human polyomavirus belonging to the genus Betapolyomavirus in 
the family Polyomaviridae. It was first isolated in 1971 from the brain of a patient, with the initials 
JC, suffering from PML, for whom the virus is named (10, 11). Polyomaviruses have been found 
in humans, monkeys, rodents, and birds . According to the International Committee on Taxonomy 
of Viruses, the family Polyomaviridae consists of four genera: Alphapolyomavirus with members 
Merkel cell polyomavirus (MCPyV) and Trichodysplasia spinulosa-associated polyomavirus 
(TSPyV), Betapolyomavirus with the species simian vacuolating virus 40 (SV40), BK 
polyomavirus (BKPyV), and JCPyV; Deltapolyomavirus including orphan human viruses human 
polyomavirus 6 (HPyV6) and 7 (HPyV7); and Gammapolyomavirus with respective 
polyomaviruses infecting birds (13, 14) .  In addition to JCPyV, the polyomaviruses that have the 
ability to infect humans include BKPyV, KIPyV, WUPyV, MCPyV, TSPyV, HPyV6, HPyV7, HPyV9, 





JCPyV infection is defined by serological or virological evidence of virus exposure 
including both replicative and non-replicative states (15). Serological surveys from widely 
separated geographic regions have shown that between 30-91% of healthy individuals have anti-
JCPyV-specific antibodies (Table 1) (16). Although JCPyV is prevalent in urban populations, 
isolated and rural Pacific island populations demonstrate antibody acquisition in early childhood 
that remained stable throughout adult life (15, 17, 18). Infection usually occurs during childhood 
and is typically subclinical. The route of JCPyV transmission and the primary sites of replication 
are unknown. Viruria is common (20-23) in which JCPyV is detected in urine. Therefore, 
transmission via urine to oral or respiratory route and primary replication in tonsillar tissue has 
been proposed . Virus-infected lymphocytes or cell-free virus presumably spread by the 
hematogenous route from the primary site to secondary sites, such as kidneys, lymphoid tissues 
and brain, to establish focal areas of infection or persistence . PCR analyses have suggested that 
JCPyV may persist in brain, tonsils and lymphocytes of individuals with or without PML , and that 





Table 1. JCPyV global seroprevalence rates 












Normal 35% (HI) 
50% (HI) 
(30) 





























USA 277 >20 Normal 69% (HI) (35) 





















86% (VP1 EIA) 
76% (VP1 EIA) 
(37) 









*VLPEIA, Virus-like particle enzyme immunoassay; HI, Hemagglutination inhibition; VP1 EIA, VP1 
enzyme immunoassay  
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STRUCTURE AND GENOME ORGANIZATION 
JCPyV has a naked icosahedral capsid and a circular double-stranded DNA genome of 
approximately 5.1 kb . The viral genome is functionally divided into an early region (2.4 kb) 
encoding large and small T antigen proteins along with the recently described T’ proteins 
generated by alternative splicing of the early mRNA; a late region (2.3 kb) encoding viral capsid 
proteins VP1, VP2 and VP3, and the accessory agnoprotein; and a non-coding regulatory region 
(0.4 kb) referred to as the noncoding control region (NCCR) (Fig. 2). Based upon the structure of 
the NCCR, two types of JCPyV have been identified: the archetypal form, which is predominantly 
detected in kidney and urine of people with and without PML (23, 41); and the rearranged form 
which is predominantly detected in brain, tonsils, and lymphocytes of individuals with PML (Figure 
2) . The archetype JCPyV NCCR, which consists of six regions, designated A to F, displays 
minimal sequence variation, whereas the NCCR of JCPyV isolated from PML patients are highly 
variable and contain rearrangements, such as deletions, duplications, tandem repeats, and 
insertions . It is thought that all other rearranged forms of JCPyV arise from the archetype form, 





Figure 2. JCPyV genome. JCPyV has a circular double stranded DNA genome about 5.13 Kb in 
length consisting of three regions: the early region, coding for the small and large T antigen; the 
late region, coding for the structural proteins VP1, VP2, VP3 and the agnoprotein; and the non-
coding control region (NCCR) or regulatory region (RR). The archetype JCPyV NCCR shows little 
variation, whereas rearranged strains are characterized by deletions, duplications, and/or tandem 





JCPyV infects cells by first binding to a receptor on the outer membranes of susceptible 
cells (Figure 3). JCPyV possesses intrinsic hemagglutination activity which allows it to engage 
alpha 2-6-linked sialic acid residues, suggesting binding to the oligosaccharide is an important 
step in JCPyV infection (46). It has also been shown that JCPyV can interact with the serotonin 
receptor 2A (5HT2AR) (47), which leads to virus internalization into glial cells. Virus is taken up 
by clatherin-dependent endocytosis (13) followed by its transportation to the nucleus where the 
removal of the viral capsid proteins occurs. Early transcription results in a primary transcript that 
is alternatively spliced into two mRNAs which code for the large T-antigen (TAg), a nuclear 
phosphoprotein that is essential for viral DNA replication, and the small t-antigen (48). Once TAg 
initiates DNA replication it stimulates transcription from the late promoter. JCPyV relies on host 
cell enzymes and cofactors for DNA replication. Since expression of these proteins are confined 
to the S-phase of the cell cycle, TAg stimulates the cell cycle by modulating cellular signaling 
pathways by binding key cellular control proteins including p53, retinoblastoma protein (pRB), and 
insulin receptor substrate 1 (IRS-1) (13, 49). Ultimately, the capsid proteins, VP1, VP2 and VP3, 
are expressed from the late region and assemble with the replicated viral DNA to form intranuclear 









Figure 3. JCPyV replication cycle. 1) JCPyV first binds to a cellular receptor complex followed 
by 2) virus internalization into the cytosol via clathrin-dependent endocytosis 3) The virus is then 
transported to the nucleus where 4) uncoating of viral DNA occurs exposing viral DNA for 5) 
early gene expression 6) Viral DNA synthesis occurs followed by 7) late gene expression 8) 
New virions are assembled and released, establishing productive infection (50). 
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PERSISTENCE AND LATENCY 
Infection with JCPyV produces a self-limiting infection in immunocompetent individuals 
with intermittent viruria. Primary JCPyV infection is cleared by the immune system to where 
viremia is undetectable, however archetype JCPyV can persist in the kidney with occasional 
viruria during low level replication within kidney cells. Prevalence of viruria varies and can be 
sporadic, but it is estimated that between 10 and 50% of healthy asymptomatic adults excrete 
JCPyV in their urine depending on the population (50-53). It is thought that JCPyV enters the 
bloodstream from its portal of entry, with the fecal-oral hypothesis implicating the nasopharynx or 
gut. JCPyV DNA has been detected in peripheral blood mononuclear leukocytes from 
immunocompetent individuals, however productive infection has not been shown (17). It is 
hypothesized that JCPyV is spread hematogenously and establishes latent infections in the 
kidneys, bone marrow, and lymphoid organs (55). Interestingly, both archetype and rearranged 
sequences are detected in peripheral blood mononuclear cells, suggesting blood may be the 





REACTIVATION AND REARRANGEMENT 
JCPyV reactivation and rearrangement are hypothesized to take place after 
immunological alterations of the host, though the exact mechanism of rearrangement remains 
unclear. NCCR structure changes in relation to anatomical sites within the same patient (42). 
Detailed analysis of JCPyV DNA populations demonstrated that the JCPyV strains from PML 
cases in cerebrospinal fluid (CSF) and/or blood often exists as a mixture of viral variants, with up 
to 10 variants in one patient. These variants could often be derived from each other by single 
duplication or deletion events, indicating a process in which the virus continuously adapts to its 
cellular environment (57). In vitro cell studies indicate that rearrangements enhance early viral 
gene expression and support higher replication rates in glial cells, increasing cytopathology (58). 
The first in vitro rearrangement of archetype JCPyV was recently demonstrated in COS-7 cells, 
green monkey kidney cells that constitutively express the SV40 large TAg protein. Two 
characteristic point mutations, T37G transversion in Spi-B binding site and G217A transition in 
NF-1 binding site were detected 28 days post transfection (59). Although it’s thought that the 
archetype virus usually gives rise to various PML-type regulatory regions by deletion and/or 
duplication, these cells were transfected for a period much shorter than that of the persistence of 
archetype strains in humans (19). Taken together, these data suggest a sequential series of DNA 
replication-driven NCCR recombination events after reactivation resulting in increased glial 





Figure 4. JCPyV dissemination and PML pathogenesis.  The events hypothesized to occur 
during the JCPyV life cycle and pathogenesis of PML are shown. Transmission of infectious 
virions is thought to occur through inhalation or ingestion of sewage-contaminated material of 
archetype JCPyV. It is then though to enter the bloodstream through the epithelium of the tonsils, 
upper respiratory tract, or gastrointestinal tract to establish primary viremia. The transmission and 
dissemination of JCPyV is not well understood, but it is thought that virus can exist as free virions 
and/or as white blood-cell associated virus. JCPyV is thought to spread to the kidney, spleen, 
bone marrow, and other secondary sites of infection via hematogenous route. In the kidneys, 
JCPyV can maintain low level replication in the epithelium of the kidney tubules where it can shed 
virions via the apical face of the kidney epithelium (60). This shedding is thought to lead to viruria 
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and transmission of infectious virions via urine, completing the JCPyV lifecycle. JCPyV may 
undergo hematogenous spread from secondary sites of infection in association with B cells, 
including the brain, where rearranged JCPyV DNA can be detected in healthy, immunocompetent 
individuals in absence of viral protein expression (61). In the environment of immunosuppression 
or immunomodulation, JCPyV can become reactivated which results in PML (62). 
 
CLINICAL AND PATHOLOGICAL FEATURES OF PML 
Primary infection with JCPyV is typically subclinical. PML is a rare clinical entity, which 
usually develops only in individuals who have underlying changes to the immune system, 
including immune suppression and immunomodulation. Clinical features of PML vary according 
to the site of demyelination and are non-specific. The most affected regions of the brain are the 
periventricular and sub-cortical regions of the parieto-occipital and frontal lobes (63, 64). Common 
presenting symptoms include cognitive deficits, gait disorders, limb weaknesses, speech 
disorders, and visual impairments .  
PML pathogenesis can be split into three phases: the first phase being a primary clinically 
inapparent infection; second phase persistent and latent peripheral infection in the urinary tract, 
bone marrow, and spleen; and the third induced by immunologic and molecular alterations of the 
viral NCCR resulting in reactivation of virulent JCPyV . The histopathological characteristics of 
PML consist of multifocal microscopic and macroscopic demyelinating lesions that tend to 
coalesce in the subcortical white matter near the grey-white matter junction. Oligodendrocytes 
support productive lytic infection and when infected their nuclei become enlarged and fill with 
JCPyV eosinophilic inclusion bodies. So-called “bizarre” astrocytes appear enlarged, with multiple 





Figure 5. Histological characteristics of PML. (a) White shows areas of demyelination or 
plaques observed at low magnification in paraffin-embedded sections of PML brain tissue stained 
with luxol fast blue for myelin. (b) Bizarre, multinucleated astrocytes frequently observed in PML 
lesions. (c) Residual JCPyV-infected oligodendrocytes harboring intranuclear eosinophilic 
inclusion bodies may be observed in demyelinated plaques. (d) Electron microscopy of 
oligodendrocyte inclusions reveal 45 nm icosahedral viral particles in nucleus consistent with 




MECHANISMS OF EPIGENETIC REGULATION 
Epigenetics are the heritable changes in gene expression that do not involve changes to 
the underlying DNA sequence (70, 71). Epigenetics responds to cellular cues and environmental 
stimuli and are regulated by post-translational covalent modifications on chromatin .  Epigenetic 
events occur regularly and can be influenced by several factors including age, environment, 
lifestyle, and disease status (72). There are at least three known systems that allow for epigenetic 
DNA modulation: DNA methylation, histone modification, and non-coding RNA (Figure 6) . A 
variety of enzymes are responsible for regulation of epigenetic processes and these proteins are 
referred to as writers, erasers, or readers. Writers covalently add functional groups, erasers 
remove groups, and readers modify chromatin or exist as adaptor proteins required for gene 
expression. Some examples of writers include DNA methylase (DNMT), histone acetyl 
transferases (HAT), and well-studied erasers are histone deacetylases (HDAC) (72). DNMT adds 
a methyl group to the fifth carbon position of a cytosine residue, typically on a 5’-CpG-3’sequence, 
preventing transcription factor binding and attenuating transcription (72). HAT catalyzes the 
transfer of an acetyl group to the histone lysine residue which changes the overall charge between 
the DNA-histone complex resulting in a relaxation of the chromatin. This leads to increased 
transcriptional access and gene expression (72). HDACs are a class of enzymes responsible for 
the removal of acetyl groups, which lead to a tighter binding of histones to DNA and decreasing 
transcriptional access (72). HAT and HDAC can also add or remove acetyl groups from proteins 





Figure 6. Mechanisms of epigenetic regulation. Histone modifications together with DNA 
methylation and micro-RNAs are dynamic processes that lead to chromatin remodeling and 
modulate gene expression without changing the underlying DNA sequence. DNA methylation at 
CpG sequences prevent binding of transcription factors and associated proteins to attenuate gene 
expression. Histones can undergo eight known modifications including acetylation, methylation, 
phosphorylation, sumoylation, and ubiquitination, however acetylation remains the most 
understood mechanism. Histone acetylation is modulated by histone acetylases (HATs) and 
histone deacetylases (HDACs). Acetylation alters the overall charge on the histone and weakens 
the DNA-histone interaction, leading to increased transcriptional access. Micro-RNAs are 
involved in post-transcriptional control of genes, binding complementary mRNA sequences and 





The importance of epigenetic-modulating enzymes in gene regulation has prompted the 
use of inhibitors for various medical reasons, including cancer therapies, allograft rejections, and 
neurodegenerative diseases (74). Next generation sequencing has demonstrated that more than 
50% of cancers harbor mutations in enzymes involved in chromatin organization (75). One 
advantage of epigenetic therapies is that they act on the transcriptional level, theoretically 
enabling repression of certain genes or transcriptional reactivation of epigenetically silenced 
genes. Additionally, the inhibition of one epigenetic regulator could have the same effect 
simultaneously on different cell processes if these pathways are targeted with a specific drug. 
These factors, in addition to the reversible nature of epigenetic treatments, make epigenetic 
targets a promising alternative for diseases which are difficult to treat using conventional 
approaches. Current inhibitors act on three epigenetic levels: DNA methylation, histone 
methylation or acetylation, and chromatin reading (Figure 7) (74). To date, there are two DNMT 
inhibitors (DMNTi) and four HDACi approved by the FDA to treat myelodysplastic syndromes 








Figure 7. Epigenetic inhibitors and their targets. Current epigenetic inhibitors act on three 
different epigenetic levels: DNA methylation, histone methylation or acetylation, and chromatin 
reading. This figure shows the most promising drugs and target proteins involved in these 





HISTONE DEACETYLASE INHIBITORS 
In the human genome, 18 HDAC family members have been identified and classified into 
four groups based on their homology to yeast HDACs. Class I HDACs are primarily located in the 
nucleus of the cell, whereas Class IIA is localized to the cytoplasm but can be shuttled between 
the cytoplasm and nucleus depending on their phosphorylation status . The remaining HDAC 
classes are mostly distributed in the cytoplasm and mitochondria. HDACs can modify other 
cellular proteins in addition to histones, and HDACi can influence a variety of processes including 
cell cycle arrest, angiogenesis, immune modulation, and apoptosis by targeting non-histone 
proteins. HDACi are grouped into four major structural classes: hydroxamic acid derivatives, 
including vorinostat and panobinostat; benzamide derivatives like mocetinostat; short chain fatty 
acids such as valproic acid; and natural inhibitors like trichostatin A, isolated from Streptomyces 
hygroscopicus (74). Most HDACi’s target multiple classes of HDACs and are recognized as pan-
HDAC inhibitors (79). In addition to their application in cancer therapies, HDACi have recently 
been investigated for a possible role in achieving a sterilizing cure for human immunodeficiency 
virus (HIV) infection. The most significant barrier to an HIV cure is the presence of replication-
competent provirus in resting CD4 T cells. If the cells remain transcriptionally silent, viral proteins 
are not produced, and the cell is invisible to the immune system and unresponsive to antiretroviral 
therapy. HIV latency is partially controlled by the activity of HDACs, which repress proviral 
transcription (80, 81). HDACi are aimed at activating HIV from latency to induce viral replication 
and allow immune-mediated elimination to occur, known as the “shock and kill” method. However, 
these HDACi may exert unwanted effects due to their non-specific inhibition. Notably, HDACi 
treatment caused defects in T-cell development and distorted CD8+ T cell activity, possibly 
reducing the potential of these cells to effectively eliminate reactivated cells in patients . 
Additionally, whether these HDACi can cause reactivation of other latent viruses in human 




Epigenetic regulation is now recognized as a ubiquitous mechanism to control gene 
expression and there are multiple examples in which viral proteins interact with the epigenetic 
machinery to modulate host and viral gene transcription . These interactions can be classified in 
two general ways: host epigenetic regulation of viral proteins or viral regulation of host 
epigenetics, both of which contribute to viral infection. An increasing body of evidence shows that 
histone modifications have critical roles in modulating viral gene expression and controlling viral 
life cycles, especially for those viruses exhibiting two distinct life cycles: latent and lytic productive 
stages (84). HIV has numerous well-documented interactions with the host-epigenetic machinery. 
An unbiased interaction study between HIV and host acetylation factors found a high degree of 
interplay: 19 of 26 HATs, 6 of 18 HDACs, and 16 of 46 bromodomain-containing proteins bind to 
diverse HIV proteins (82). Protein and chromatin acetylation have documented roles in HIV viral 
fusion and entry, HIV transcription, and HIV latency (82).  
The effect of active histone markers in virus lytic infection or reactivation from latency has 
been observed in multiple viruses but have been best characterized in Kaposi’s sarcoma-
associated herpesvirus (KSHV) (85), Epstein-Barr virus (EBV) (83), human cytomegalovirus (86), 
and HIV (86-88). Epigenetic interactions have also been well documented within the polyomavirus 
family. SV40 has been extensively studied as a model virus, and it has been demonstrated that 
SV40 undergoes almost all of the same forms of epigenetic regulation as cellular chromatin, 
including nucleosome location, histone modifications, and miRNAs. However, polyomaviruses do 
not appear to utilize DNA methylation as a form of epigenetic regulation due to their small genome 
size and relative absence of CpG target sites for methylation. Many polyomaviruses, including 
SV40 and JCPyV, contain a miRNA in the late message strand which can be cleaved to yield an 
miRNA which inhibits expression of the early genes. These viral miRNAs shares sequence 
homology with certain cellular miRNAs and it has been suggested that the viral miRNAs could 
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dysregulate cellular genes (90).  Interestingly, it has recently been shown that SV40 chromatin 
from virus particles before infection and after infection results in a shift in nucleosome location, 
exposing the early and late start sites which were previously bound by the nucleosome (91). 
Although other polyomaviruses have not been studied to the extent of SV40, they have similar 
replication strategies and genomes and likely utilize epigenetics in comparable ways to regulate 
infection.  
 
EPIGENETICS AND JCPyV 
Recently, epigenetic events have been implicated in regulatory control of JCPyV early and 
late gene transcription. Transfection of Mad-1 JCPyV into TC620 human oligodendroglioma cells 
treated with HDACi trichostatin A (TSA) and sodium butyrate stimulated JCPyV early and late 
gene transcription (92, 93). Further transfection experiments utilizing mutations in the archetype 
NCCR showed the protein acetylation events affect the nuclear factor kappa-light-chain-enhancer 
of activated B cells (NF-κB) p65 protein’s binding to the NCCR , but not with DNA 
methyltransferase inhibitors, suggesting that viral gene expression is regulated by events that 
involve protein acetylation. The effect was found to be mediated via the κB element, a site located 
within the NCCR responsible for: 1) binding transcription factors NF-kB p65, CCAAT/Enhancer 
binding protein beta (C/EBPβ), nuclear factor of activated T-cells 4 (NFAT4), and Rad51, and 2) 
mediating stimulation by tumor necrosis factor alpha (TNF-α) . Further site-directed mutagenesis 
studies showed that protein acetylation events at specific lysine residues in NF-kB p65 impaired 
or enhanced transactivation of JCPyV early promoter transcription. This suggests acetylation 
regulates NF-kB p65 activity toward Mad-1 JCPyV at the level of p65 binding to the JCPyV NCCR 
and activation of early viral protein transcription (94).  
A separate study supported these findings by investigating the role of Brd4, an epigenetic 
reader protein that recognizes acetylated lysine residues and specifically binds to acetylated NF-
kB p65. A Brd4 inhibitor blocked transcription of early genes and reactivation of infection, further 
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implicating epigenetic regulation by histone acetylation as a critical step in regulation of early Mad-
1 JCPyV virus transcription (42). Although in healthy individuals, JCPyV exists as a persistent 
latent infection in viral reservoirs, in immunocompromised patients the virus undergoes 
rearrangements and reactivation into a more pathogenic virus which leads to PML (1). The effects 
of epigenetic drug-modulated immunosuppression on JCPyV latency and reactivation are not well 
understood. Thus, there is a gap in our understanding of the effects of epigenetic drug-modulated 
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Background and rationale 
The mechanisms which control JCPyV reactivation and PML pathogenesis have not been 
defined, although host immune status has been implicated as a critical factor. However, even 
within immunocompromised patients only a subset of these individuals will develop PML, 
indicating a more nuanced modulatory role of the immune system in PML development. 
Epigenetics is a rapidly expanding field whose systems have critical regulatory roles in various 
cellular processes including cell cycle arrest, angiogenesis, immune modulation, and apoptosis. 
With the advent of new epigenetic therapies, it is important to understand the effect of epigenetic 
control on the replication and reactivation of JCPyV for risk stratification and potential 
therapeutics. Since epigenetic drug-modulated immunosuppression of JCPyV latency and 
reactivation are not well understood, there is a gap in our understanding of the effects of 
epigenetic drug-modulated immunosuppression on the reactivation and rearrangement of 
archetype JCPyV. 
 
Long-term goal, Objective, and Hypothesis 
Our long-term goal is to delineate the natural history of archetype JCPyV infection, 
reactivation, and rearrangement for evidence-based approaches to improve treatment for PML. 
The objective of this research is to determine the epigenetic regulation of archetype JCPyV. The 
aims of the proposed research are to determine the effects of HDACi on urine-derived archetype 
JCPyV replication kinetics in vitro and JCPyV viruria and NCCR sequences in HIV-infected 
individuals on uninterrupted combination antiretroviral therapy (cART) treatment with HDACi 
panobinostat. We hypothesize that archetype JCPyV infection is regulated epigenetically by 







Specific Aim 1: Determine the effect of HDACi trichostatin A (TSA) on the replication 
kinetics of archetype JCPyV in vitro.  
Specific Aim 1a: Investigate the effect of TSA on the replication kinetics of urine-derived 
archetype JCPyV in primary human brain cortical astrocytes (HBCA).  
Specific Aim 1b: Investigate the effect of TSA on the replication kinetics of urine-derived 
archetype JCPyV replication in primary renal proximal tubule epithelial (RPTE) cells.  
Hypothesis: Based on published literature, we hypothesize that treatment with TSA will increase 
the replication kinetics of urine-derived archetype JCPyV in HBCA and RPTE cells.  
Approach:. First, cytotoxicity will be assessed using an MTS assay. HBCA or RPTE cells will be 
seeded at 20,000 cells/well in 96-well plates maintained at 37°C, 5% CO2. At 80% confluency, 
cells will be treated with 0, 50, 100, 200 nM TSA. Cell viability will be assessed at 1, 5, 10, 15, 
and 20 days post treatment. The susceptibility of HBCA and RPTE cells to urine-derived 
archetype JCPyV infection will be monitored by detection and analysis of JCPyV DNA, RNA, 
protein, and infectious virions. Cells will be seeded at 1.5x105 cells/well in a six-well plate and 
infected with 41 HA units of JCPyV/well (1). Quantitative analysis of JCPyV genome copies and 
RNA transcripts will be conducted using qPCR and qRT-PCR assays, respectively, using JCPyV 
TAg and VP1-specific primers at 12 hours, 1, 3, 5, and 10 days after infection, as previously 
described (2). qPCR gene copies will be normalized to GAPDH. JCPyV VP1 protein will be 
detected by immunofluorescence assay (IFA) in archetype JCPyV-infected cells at 15 and 25 
days after infection (3). NCCR sequence analysis will be conducted in infected cells at days 1 and 
10 following archetype JCPyV infection. To demonstrate the production of infectious archetype 
JCPyV virions, naïve cells will be infected with supernatant from previously infected cells collected 
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at day 15 or 20 after infection. Viral DNA and RNA will be quantitated by qPCR as described 
above. 
Data Analysis: All experiments will be performed in duplicate and repeated at least once. For 
qPCR and qRT-PCR analysis, average cycle threshold (CT) values will be log transformed, mean 
centered, and autoscaled in order to draw statistical comparison as previously described (4). 
qPCR and qRT-PCR data will be from two biological replicates. Error bars will indicate 95% 
confidence intervals, and asterisks will indicate Welch-modified t test p values of less than 0.05, 
0.01, and 0.001 as previously described (2). 
Specific Aim 2: Determine the effect of HDACi panobinostat treatment on viruria and NCCR 
sequence of JCPyV in HIV-infected individuals on uninterrupted cART.  
Specific Aim 2a: Determine the effect of panobinostat treatment on JCPyV viruria in HIV-
infected individuals on uninterrupted cART. 
Specific Aim 2b: Determine mutations in JCPyV NCCR sequence isolated from HIV-
infected individuals on uninterrupted cART treated with panobinostat.  
Hypothesis: Based on the published literature, we hypothesize that panobinostat treatment will 
increase JCPyV excretion in the urine than in baseline untreated measurements. We also 
hypothesize that the panobinostat-treated HIV-infected individuals may have mutations and 
rearrangement events within the NCCR region of the archetype JCPyV. 
Approach: HIV-infected individuals who were treated with 20 mg oral panobinostat while on 
uninterrupted cART will be screened for JCPyV by PCR and the NCCR region from JCPyV-
positive urine samples were sequenced. Randomized blinded patient urine samples from the 
CLEAR cohort (clinical trial # NCT01680094) (5) will be first screened for JCPyV DNA by 
conventional PCR. DNA will be extracted from urine samples using QIAprep Spin Miniprep kit 
using previously described protocols. Conventional PCR of the NCCR region primers (JRR 25 
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and JRR 28) and VP1 region primers (JLP 15 and JLP 16) will be used as previously described 
[50-51]. JCPyV DNA-positive samples will undergo quantitative analysis of JCPyV genome copies 
by qPCR specific for TAg and VP1 normalized to GAPDH, as previously described (4). Additional 
NCCR sequence analysis will be conducted for JCPyV-positive urine samples as previously 
described (6). 
Data Analysis: All experiments will be performed in duplicate and repeated at least once. For 
qPCR analysis, average cycle threshold (CT) values will be log transformed, mean centered, and 
autoscaled in order to draw statistical comparison as previously described (4). Error bars will 
indicate 95% confidence intervals, and asterisks will indicate Welch-modified t test p values of 
less than 0.05, 0.01, and 0.001 as previously described (2). NCCR from panobinostat-treated 
JCPyV-infected HIV-positive individuals will be sequenced and analyzed for mutations, deletions, 
and or duplications compared to archetype JCPyV NCCR. 
Significance 
JCPyV remains an elusive virus to study, partly due to the difficulty of propagating the 
archetype virus in vitro and the lack of an animal model of disease. Nearly 40 years after the 
discovery of JCPyV, there remains no therapeutic treatment for the devastating disease PML or 
vaccine for prevention of JCPyV infection. The widespread seroprevalence of JCPyV in the 
general population further emphasizes the need to understand the molecular mechanisms that 
underly JCPyV infection and PML development. Further, with the new wave of immunomodulatory 
and epigenetic drugs in development and coming to market, understanding JCPyV infection in 
the context of nonspecific pharmaceutical immune modulation will be critical. This study is 
significant in that it utilizes a primary cell model to investigate the effect of HDACi on JCPyV 
replication in vitro, as well as in patient samples. Insight into these mechanisms may contribute 




Epigenetics is an important aspect to consider in the context of viral infection as it has 
been implicated as a major factor in viral latency. Elucidating the molecular mechanisms involved 
in epigenetic events will drive development of therapeutic agents to disrupt viral latency and 
increase immune surveillance. One well-known example in which this type of approach has been 
utilized is in development of new HIV therapeutics. Due to the integration of HIV into the host 
genome and complexity of viral latency, curative therapy has long thought to be unfeasible. 
However, recently viral reactivation from latently infected cells has become a promising 
therapeutic approach to eradicate HIV. Using treatment to reactivate HIV from its latent reservoirs 
followed by cART to kill the activated virus is one potential approach to achieve a sterilizing cure. 
In JCPyV, transcription of rearranged JCPyV early genes in transfected oligodendroglioma cells 
can be enhanced with the use of HDACi . Based on the published literature, this effect is due to 
the acetylation of transcription factor NF-kB p65.  
Although these studies examined HDACi modulation of JCPyV, it has always been in the 
context of transfection utilizing the rearranged virus rather than infection with the archetype virus. 
This is primarily due to the complexity in isolating and cultivating live archetype JCPyV from 
infected individuals, as well as difficulty in identifying a primary cell culture model. The innovation 
of this study will be the use of archetype JCPyV isolated from a healthy individual to infect primary 
cell cultures treated with epigenetic inhibitors. This model system was developed in our laboratory 
and is more biologically relevant than transfections as it utilizes the natural course of JCPyV 
attachment to host cell receptors, internalization, and replication. Additionally, JCPyV viruria and 
NCCR sequences have not been assessed in vivo in individuals who were treated with HDACi. 
Understanding the molecular mechanisms underlying the effects of epigenetic inhibitors on 
JCPyV infection and replication in vitro and in vivo will drive development of more effective 
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The human polyomavirus JC (JCPyV) is the causative agent of progressive multifocal 
leukoencephalopathy (PML), a demyelinating disease of the brain. Although archetype JCPyV 
infection is common in the healthy population, PML occurs almost exclusively in individuals with 
immunodeficiencies or on immunomodulatory medication, particularly HIV-1/AIDS patients and 
patients on monoclonal antibody regimens. After primary infection and dissemination, replication 
is controlled by the immune system, causing an asymptomatic infection with occasional viruria. 
However, when immune function is perturbed, JCPyV can re-emerge as a rearranged virus, with 
deletions and/or duplications in the non-coding control region (NCCR). This rearranged JCPyV 
virus can undergo lytic replication in the oligodendrocytes and astrocytes, causing PML. 
Therefore, a crucial question in understanding PML pathogenesis is the nature of the molecular 
mechanisms which maintain JCPyV latency. Epigenetic regulation is now recognized as a 
ubiquitous mechanism to control gene expression. The JCPyV genome structure closely 
resembles host chromatin, and it is possible that these mechanisms modulate JCPyV replication. 
Histone deacetylase inhibitors (HDACi) have been demonstrated to increase rearranged JCPyV 
replication in a transfection model. We used patient-derived archetype JCPyV to infect primary 
human brain cortical astrocytes (HBCA) and renal proximal tubule epithelial cells (RPTE) treated 
with HDACi trichostatin A (TSA). Treated HBCA ad a four-log fold increase in genome copy 
numbers at 12 h post infection, while RPTE cells showed a 20 to 30-fold increase at day 10. TSA-
treated HBCA showed a slight increase in RNA transcripts, while RPTE cells demonstrated a 30 
to 60-fold increase in RNA transcripts 10 days post infection. TSA treatment also rescued VP1 
protein production in HBCA and increased VP1 production two-fold in RPTE cells, although 
infectious virions were only detected in RPTE cells. To our knowledge, this is the first study to 
show the effect of HDACi on archetype JCPyV replication in an in vitro infection model. Taken 
together, our data demonstrates that TSA treatment in primary HBCA and RPTE cells increases 
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both early and late archetype JCPyV replication in a cell-specific manner. Further studies are 





Human polyomavirus JC (JCPyV) is the causative agent of progressive multifocal 
leukoencephalopathy (PML), a demyelinating disease of the brain. PML was originally recognized 
as a rare complication of hematological malignancies or systemic inflammatory disorders, 
however incidence increased rapidly during the AIDS epidemic (1). AIDS is the most frequent 
condition associated with PML (2), with approximately 6% of patients developing AIDS related 
PML (3). A resurgence of PML occurred in the 2000s as a result of the use of immunomodulatory 
compounds, including monoclonal antibodies natalizumab, efalizumab, and rituximab, for the 
treatment of the autoimmune conditions, such as multiple sclerosis, Crohn’s disease, severe 
forms of plaque psoriasis, hematologic malignancies, and rheumatoid arthritis (4). Currently, there 
is no treatment for PML or vaccine against JCPyV. 
JCPyV is a neurotropic human polyomavirus belonging to the genus Orthopolyomavirus 
in the family Polyomaviridae. It was first isolated in 1971 from the brain of a patient suffering from 
PML (5). Infection with JCPyV produces a self-limiting infection in immunocompetent individuals 
with intermittent viruria (6-8). The route of JCPyV transmission and the primary sites of replication 
are unknown. JCPyV is detected in human sewage, so transmission via urine to oral or respiratory 
route and primary replication in tonsillar tissue has been proposed . Primary JCPyV infection is 
cleared by the immune system to where viremia is undetectable and is thought to persist in the 
kidneys.  
JCPyV has a naked icosahedral capsid and a circular double-stranded DNA genome of 
approximately 5.1 kb . The viral genome is functionally divided into an early region encoding large 
and small T antigen proteins; a late region (2.3 kb) encoding viral capsid proteins VP1, VP2 and 
VP3, and the accessory agnoprotein; and a non-coding regulatory region (0.4 kb) referred to as 
the noncoding control region (NCCR).  Based upon the structure of the NCCR, two types of JCPyV 
have been identified: the archetypal form, which is predominantly detected in kidney and urine of 
people with and without PML (8); and the rearranged form which is predominantly detected in 
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brain, tonsils, and lymphocytes of individuals with PML (9,10) . The archetype JCPyV NCCR, 
which consists of six regions, designated A to F, displays minimal sequence variation, whereas 
the NCCR of JCPyV isolated from PML patients are highly variable and contain rearrangements 
such as deletions, duplications, tandem repeats, and insertions in the NCCR . It is thought that all 
other rearranged forms of JCPyV arise from the archetype form within the patient, and most likely 
arise during immunosuppression or immunomodulation (10,11).  
JCPyV is a DNA virus with no transcription factors in the infectious virion, therefore it is 
highly dependent on host and cellular transcription machinery to initiate the early phase of 
transcription. Similar to human DNA, JCPyV DNA is tightly wound around host-derived positively-
charged histone proteins in a chromatin-like complex (12-13). This complex is subject to 
regulation by epigenetics, which include histone modifications that alter the chemical charge of 
the DNA-histone complex modulating access to transcription machinery. Histone acetylation is a 
well-studied histone modficiation in which histone acetylases (HAT) add acetyl groups to the 
histones. This causes the charge on the histones to become more neutral, weakening the 
association of the DNA-histone complex and allowing for a more open chromatin conformation, 
generally associated with an increase in transcription. This process is reversed by histone 
deacetylases (HDAC), which remove the acetyl groups and is generally associated with 
transcription repression.  
Recently, epigenetic events have been implicated in regulatory control of JCPyV early and 
late gene transcription. Transfection of Mad-1 JCPyV into TC620 human oligodendroglioma cells 
treated with HDACi trichostatin A (TSA) and sodium butyrate stimulated JCPyV early and late 
gene transcription (14). Further transfection experiments utilizing mutations in the archetype 
NCCR showed the protein acetylation events affect the nuclear factor kappa-light-chain-enhancer 
of activated B cells (NF-κB) p65 protein binding to the NCCR , but not with DNA methyltransferase 
inhibitors, suggesting that viral gene expression is regulated by events that involve protein 
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acetylation. The effect was found to be mediated via the κB element, a site located within the 
NCCR responsible for: 1) binding transcription factors NF-kB p65, CCAAT/Enhancer binding 
protein beta (C/EBPβ), nuclear factor of activated T-cells 4 (NFAT4), and Rad51, and 2) mediating 
stimulation by tumor necrosis factor alpha (TNF-α) . Further site-directed mutagenesis studies 
showed that protein acetylation events at specific lysine residues in NF-kB p65 impaired or 
enhanced transactivation of JCPyV early promoter transcription. This suggests acetylation 
regulates NF-kB p65 activity toward Mad-1 JCPyV at the level of p65 binding to the JCPyV NCCR 
and activation of early viral protein transcription (15). A separate study supported these findings 
by investigating the role of Brd4, an epigenetic reader protein that recognizes acetylated lysine 
residues and specifically binds to acetylated NF-kB p65. A Brd4 inhibitor blocked transcription of 
early genes and reactivation of infection, further implicating epigenetic regulation by histone 
acetylation as a critical step in regulation of early Mad-1 JCPyV transcription (16).   
To date, experiments with JCPyV have routinely used the rearranged Mad-1 JCPyV in 
transfection models due to the difficulty in isolating and culturing archetype JCPyV. The novelty 
of this study is to investigate the role of epigenetics in archetype JCPyV infection, using a patient-
derived archetype JCPyV and an infection model in primary cells. We used two different in vitro 
models, renal proximal tubule epithelial cells (RPTE) and primary human brain cortical astrocytes 
(HBCA), as the kidneys are a hypothesized place of latency and the brain is the area of disease 
pathogenesis. We demonstrated that treatment with TSA increased archetype JCPyV DNA and 
RNA and stimulated JCPyV late protein production. Further, we demonstrated infectious virion 
production in RPTE cells but not HBCA. Together, we demonstrated that HDACi TSA increases 





TSA is not cytotoxic to HBCA and RPTE cells 
To ensure cell viability would not be affected by treatment, a cytotoxicity assay was 
performed with multiple epigenetic inhibitors (Supplementary Fig. 1). Two HDACi, TSA and 
suberoylanilide hydroxamic acid (SAHA), were purchased from Sigma Aldrich. HBCA and RPTE 
cells were cultured with varying concentrations of TSA and SAHA for 20 days and cell viability 
was assessed by an MTS assay on days 1, 5, 10, 15, and 20. The physiological concentrations 
of TSA and SAHA used were based on previous reports which utilized 200 nM TSA and 5 mM 
SAHA which resulted in a 10-fold increase in Mad-1 JCPyV luciferase transcription reporter 
activity respectively (16). SAHA was highly cytotoxic at 5, 10, and 20 µM concentrations to 
HBCA and RPTE cells, resulting in a 50% reduction in cell viability at higher concentrations just 
one day after treatment (Supplemental Fig. 1A). Subsequent experiments with SAHA at 0.625, 
1.25, and 2.5 µM showed moderately cytotoxic effects, with a 30% reduction in viability at day 
20 (Supplemental Fig. 1B). TSA at 50, 100, and 200 nM showed no difference in cytotoxicity in 
both HBCA and RPTE cells (Supplemental Figure 1C). Therefore 200 nM TSA was used for all 
subsequent experiments.  
 
JCPyV early and late transcription are enhanced by HDACi TSA 
In at least two independent experiments, the replication kinetics of archetype JCPyV in 
200 nM TSA-treated primary HBCA and RPTE cells was monitored from day 1 to 10 after 
infection. The viral titer of the urine-derived archetype JCPyV virus was determined using an HA 
assay (Supplementary Fig. 2). 1.5x105 cells were inoculated with 41 HA units of archetype JCPyV 
and quantitative analysis of JCPyV TAg and VP1 genome copies and RNA transcripts were 
conducted by qPCR and qRT-PCR. At 12H after infection, the total JCPyV TAg (2.58x108) and 
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VP1 (2.58x108) genome copies recovered from treated HBCA showed a four-log fold increase in 
TAg (1.34x104) and VP1 (1.23x104) compared to control untreated cells (Fig. 1A). At day 10, the 
total mean genome TAg (4.08x109) and VP1 (1.31x1010) copies recovered from each 35 mm plate 
seeded with HBCA were approximately two-fold (2.58) and two-log fold (1.27x102) higher than 
untreated cells. Treated HBCA showed no fold increase in TAg transcripts but a larger (11.1) fold 
increase in VP1 transcripts. In treated RPTE cells, total JCPyV TAg (8.71x1012) and VP1 
(4.37x1011) genome copies recovered at day 10 post infection showed a fold increase of 36.9 and 
13.5 compared to control RPTE cells, respectively (Fig. 1B). Treated RPTE cells showed a fold 
increase of 61.6 and 96.2 for TAg and VP1 RNA transcripts at day 10 post infection, respectively. 
NCCR sequence analysis confirmed no change in sequence from infecting dose (ID) to day 10 
post infection (Supplementary Fig. 3). 
 
TSA effect on VP1 and virion production 
In two independent experiments, we examined VP1 protein production by IFA. At day 15 
post infection, approximately 2% of HBCA (Fig. 2A) and 13% RPTE cells (Fig. 2B) expressed 
JCPyV VP1 protein using IFA, compared to 0% of HBCA and 6% of RPTE untreated archetype 
JCPyV infected cells. To demonstrate production of infectious archetype JCPyV virions, naïve 
HBCA and RPTE cells were infected with virus isolated from previously infected HBCA and RPTE 
cells collected on days 20 and 15 after infection (Fig. 2C). Naïve HBCA showed no detectable 
DNA replication or RNA transcripts. DNA replication and RNA transcripts in infected naïve RPTE 





JCPyV has been known to be the causative agent of PML for more than 50 years, yet little 
is known about the basic mechanisms which maintain JCPyV latency and persistence. Although 
these mechanisms have not been clearly defined, it is known that PML primarily affects 
immunocompromised individuals. The current model suggests immune perturbance leads to 
decreased immunosurveillance and poor JCPyV specific immune control. This is thought to result 
in an increase in JCPyV viral replication, which generates JCPyV variants, which will differ in 
replication capacity and cellular tropism based on their NCCR sequences. It is thought that some 
of these high-replication capacity variants lead to viremia and migrate to the brain resulting in 
PML (11). Archetype JCPyV has been demonstrated to infect B cells and transmigrate through 
the blood brain barrier in an in vitro model (18), supporting this model of pathogenesis. 
Epigenetic regulation has been implicated in control of JCPyV latency due to the structural 
similarity of the JCPyV genome to cellular chromatin. In the last ten years, several papers have 
implicated histone acetylation in modulating rearranged JCPyV replication. These studies have 
demonstrated that histone acetylation regulates NF-kB p65 activity toward Mad-1 JCPyV and 
activates early viral protein transcription (15). However, to date these experiments have been 
performed using the rearranged JCPyV isolate Mad-1 in transfection models. There are several 
drawbacks to these models: first, that the behavior of the prevalent archetype virus cannot be 
observed, limiting the potential to understand the factors which influence the rearrangement to 
the highly pathogenic rearranged JCPyV; second, that the transfection model is artificial and does 
not mimic engagement of the host-cell surface receptors and entry steps and their downstream 
effects; and third, that the immortalized cell types used do not resemble those that would be 
infected in vivo.  
 For the first time, we demonstrate that HDACi increases archetype JCPyV replication in 
an infection model and in a cell-dependent manner. We demonstrate an increase in JCPyV DNA 
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and RNA at late time points as well as a doubling of VP1 positive cells and production of infectious 
virions in TSA-treated RPTE cells. Further, we demonstrate an increase in JCPyV DNA and RNA 
at early time points in TSA-treated HBCAs and rescue of VP1 protein production, but not infectious 
virions. The kidneys are a site of latency for archetype JCPyV as virus is detected in the kidneys 
and is excreted in urine (8). Therefore, we expected a productive infection in RPTE cells. Our 
data supports this hypothesis, and replication in RPTE cells was further driven with TSA 
treatment. The brain is the site of pathogenesis for PML, and archetype JCPyV has not been 
detected in the brain. Therefore, we did not expect a productive replication of archetype JCPyV 
in HCBA cells. However, with TSA-treatment, the rescue of VP1 production indicates the 
possibility that archetype JCPyV could productively replicate in HBCAs under specific conditions.  
Most HDACis target multiple classes of HDACs and are recognized as pan-HDAC 
inhibitors (17). In addition to their role as cancer therapeutics, HDACi have recently been 
investigated for a possible role in achieving a sterilizing cure for HIV infection. HDACi are aimed 
at activating HIV from latency to induce viral replication and allow immune-mediated elimination 
to occur, known as the “shock and kill” method. However, these HDACi may exert unwanted 
effects due to their non-specific inhibition. Notably, HDACi treatment caused defects in T-cell 
development and distorted CD8+ T cell activity, possibly reducing the potential of these cells to 
effectively eliminate reactivated cells in patients as well as being ineffective at controlling other 
infections (17). Whether these HDACi can cause reactivation of other latent viruses in human 
patients have not been evaluated. Our data strongly demonstrates the possibility of these LRAs 
in reactivating JCPyV, a ubiquitous polyomavirus for which the HIV-positive population is at a 
particular risk. This further highlights the need to study the effect of these drugs on other latent 
viruses to improve risk stratification for patients.  
Our data demonstrate the importance of histone modulation on JCPyV early and late 
transcriptional control. These epigenetic mechanisms should be investigated further, to identify 
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possible therapeutic targets and develop effective treatment for PML, as well as mitigating risk in 
patients administered HDACis. 
 
Conclusions 
We have demonstrated that TSA treatment in archetype JCPyV infected primary HBCA 
and RPTE cells increases both early and late replication in a cell-specific manner. Treated HBCA 
had a higher fold increase in genome copy number, while RPTE cells demonstrated a larger 
increase in RNA transcripts. TSA treatment also rescued VP1 protein production in HBCA and 
increased production in RPTE cells, although infectious virions were only detected in RPTE cells. 
To our knowledge, this is the first study to show the effect of HDACi on archetype JCPyV 
replication in an infection model. Further studies are needed to understand the exact mechanism 
of regulation in archetype JCPyV replication within HBCA and RPTE cells. Differentiating the 
mechanisms which control JCPyV latency in glial and nonglial cells is crucial to understanding 




Materials and Methods 
Cell culture 
Primary HBCA were purchased from Cell Systems Corporation and maintained as 
previously described . Primary RPTE cells (Cat #4100) were purchased from Sciencell. HBCA 
and RPTE cells between passages P6 and P9 were used in all experiments.  
 
Virus 
Archetype JCPyV was isolated from the urine of healthy volunteers after obtaining written 
informed consent and study approval by UH-CHS by former graduate student Dr. Nelson Lazaga. 
Urine collected from healthy individuals were stored at 4°C and processed as previously 
described (18). DNA was extracted using Qiagen QIAprep Spin Miniprep Kit according to 
manufacturer’s protocol. Urine-isolated JCPyV was then quantitated by real-time PCR (qPCR) 
(19) and confirmed by sequencing the NCCR as previously described (18). To generate archetype 
virus stock, COS-7 cells were infected with urine-derived JCPyV and harvested at day 35 after 
infection. Virus isolation and purification was conducted as previously described (20). Virus was 
then quantitated by HA assay (20) and qPCR prior to infection experiments and confirmed by 
NCCR sequence analysis before and after infection. 
 
HA assay 
VP1 is the major capsid protein of the JCPyV and it is responsible for the attachment to 
cells and agglutinates  human type O erythrocytes (20). Human type O erythrocytes were 
centrifuged at 2,500 rpm for 10 min at 4oC, washed twice in Alsever’s buffer (20 mM sodium 
citrate, 72 mM NaCl, 100 mM glucose, pH 6.5 adjusted with acetic acid), and suspended in 
53 
 
Alsever’s buffer at a final concentration of 0.5%. Serial two-fold dilutions of virus suspensions 
were prepared in Alsever’s buffer. Fifty µL of viral suspension and an equal volume of RBC were 
added to each well of a 96-well “U” bottom microtiter plate and incubated at 4oC for 3 to 6 hours, 
with a final volume of 100 µL. The final dilution of virus suspension that agglutinates red blood 
cells was considered the end point of the titration and read as the reciprocal of that dilution. The 
end point dilution is considered 1 hemagglutination (HA) unit, with the estimated ratio of infectious 
particles being approximately 104 to 1 HA unit . 
 
JCPyV infection 
1x105 HBCA or RPTE cells were seeded in tissue culture treated 35-mm plates to study 
viral kinetics. Additionally, 5x104 cells were seeded in each well of a 24-well plate containing cover 
slips for immunofluorescence assay (IFA). At 80 to 90% confluency, cells were either mock-
infected with medium only, or inoculated with 41 HA units of JCPyV per 1x105 cells. Initial virus 
inocula were measured using qPCR, prepared at appropriate concentrations, and added into 
designated plates, wells, or flasks and returned to an incubator (37oC with 5% CO2) for 2 hour 
adsorption for archetype JCPyV. Each plate, well, or flask was then washed twice with 1X PBS 
to remove unadsorbed virus followed by replenishment of fresh medium. Wells, plates, and flasks 
were kept at 37oC with 5% CO2 until time of cell harvest at designated time points. Culture medium 
was changed every three days. 
 
TSA treatment 
HBCA and RPTE cells were treated after infection and followed by continuous treatment 
until designated harvest time points. Culture media with TSA was changed every three days. TSA 




Cytotoxicity was assessed using the Promega Cell Titer 96® AQueous One Solution 
Reagent MTS assay, according to the manufacturer’s protocol. Briefly, 20 µL of reagent was 
added into each well, incubated at 37°C, 5% CO2 for 4 hours. Absorbance at 490 nm was read 
using a 96 well plate reader. 
 
Reinfection of naïve cells 
At 80 to 90% confluency, cells were infected with 41 HA units of archetype JCPyV per 
1x105 cells. Media was changed every two days and cell lysates were collected for DNA and RNA 
analysis. For the reinfection of naïve HBCA or RPTE cells, 15 or 20 days after infection, infected 
cells were subjected to virus isolation and purification as previously described (18). Initial virus 
inoculum was measured using qPCR and naïve HBCA or RPTE cells were reinfected, as 
mentioned above. 
 
DNA and RNA extraction and quantitative analysis 
Low molecular weight DNA and total RNA were extracted from mock- and archetype 
JCPyV-infected cells from 35-mm plates harvested at 12 hours, day 1, 3, 5, and 10 after infection 
or days 1, 5, 10, 15, and 20 after reinfection, as previously described (19). cDNA was synthesized 
from 1 µg of cellular RNA using Bio-Rad iScript cDNA synthesis kit following the instructions 
provided by the manufacturer. JCPyV DNA or cDNA was amplified using 2 µL of template DNA 
or cDNA, 10 pmol each of forward and reverse primers, and probe specific for JCPyV TAg and 
for VP1 genes in a final reaction volume of 20 µL as previously published by our group and 
normalized to GAPDH (19). qPCR was conducted using a Bio-Rad iCycler iQ™ Multicolor Real-
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Time PCR Detection System. Analysis was conducted via Bio-Rad iCycler iQ™ Multicolor Real-
Time PCR Optical System Software Version 3.1.  
 
PCR amplification and sequence analysis 
JCPyV NCCR was amplified using 2 µL of template DNA and primers JRR-25 and JRR-
28 as described previously (21). PCR products were separated on a 2% agarose gel, visualized 
with ultraviolet light, and purified by QIAquick PCR purification column and sequenced for positive 
identification of archetype JCPyV.  
 
Immunofluorescence assay 
HBCA and RPTE cells were seeded on coverslips in 24-well pates (5x104 cells/well). Cells 
were either mock-infected with medium only or inoculated with 20.5 HA units of archetype JCPyV. 
Cell preparation and staining with various primary antibodies were conducted as previously 
described (18). Fluorescent cells were examined using an Axiocam MRm camera mounted on a 
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Figure 1. TSA treatment increases archetype JCPyV DNA and RNA expression in HBCA 
and RPTE cells. (A) HBCA or (B) RPTE cells were infected with 41 HA units of COS-7 cell 
propagated urine-isolated archetype JCPyV per well and incubated for 2 hours. Immediately 
following infection, cells were washed with PBS and fresh media with or without 200 nM TSA was 
added. Treatment continued until cells were harvested at indicated time points. DNA and RNA 
were extracted and viral TAg and VP1 genome copies and RNA transcripts were quantitated by 
























Figure 2. VP1 protein and reinfection of naïve HBCA and RPTE cells. Immunofluorescence 
staining was conducted on (A) HBCA and (B) RPTE cells infected with archetype JCPyV at day 
15 after infection and cells were stained using anti-VP1 mouse monoclonal Ab (green) and DAPI 
(blue), scale bar 20 µm. (C) Naïve HBCA and RPTE cells were infected with 41 HA of archetype 
JCPyV isolated from previously infected HBCA and RPTE cells. Reinfection of isolated archetype 
JCPyV in RPTE cells TAg and VP1 genome copies and RNA transcripts are shown. There was 
no detectable DNA or RNA in the reinfected HBCA. 
C. 
B. 











Supplemental Figure 1. Cytotoxicity of various epigenetic inhibitors in HBCA and RPTE 
cells: HBCA or RPTE cells were treated with (A) 5, 10, 20 µM SAHA, (B) 0.625, 1.25, 2.5 µM 
SAHA, (C) 50, 100, 200 nM TSA, (D) 1, 5, 25 µM AZA, and (E) 5, 10, 20 µM ANA. At the 
indicated time points cell viability was assayed using Promega’s CellTiter 96® AQueous ONE 
Solution Cell Proliferation Assay System following the manufacturer’s protocol. Absorbance at 




Supplemental Figure 2. HA assay to determine infectious dose. Type O negative, JCPyV 
seronegative blood was incubated with increasing dilutions of virus stocks. The final dilution of 
virus suspension that agglutinates red blood cells was considered the end point of the titration 
and read as the reciprocal of that dilution. The end point dilution is considered 1 hemagglutination 
(HA) unit, with the estimated ratio of infectious particles being approximately 104 to 1 HA unit. A 









Supplemental Figure 3. NCCR sequencing of archetype JCPyV infection experiment. DNA 
was extracted from infecting dose (ID) and final collection day (D10 I). Samples underwent PCR 
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Combination antiretroviral therapy (cART) controls replication of HIV-1 by affecting 
different stages of the viral life cycle. The use of cART has led to a prolongation of the lifespan of 
HIV-positive individuals and an improvement in quality of life, transforming HIV infection from a 
life-threatening disease into a chronic infectious disease. Despite the efficacy of cART, it is unable 
to completely eliminate infected cells and treatment is lifelong. One of the main obstacles to 
curative HIV treatment is the existence of proviral DNA in memory CD4+ T cells, which retain the 
potential to produce new viruses. A new approach to curative treatment is the “shock and kill” 
method, which reactivates these latent cells with latency reversal agents (LRA) and uses cART 
to eliminate reservoirs. However, the ability for these histone deacetylase inhibitors (HDACi) 
ability to reactivate HIV suggests the possibility of reactivation of other latent viruses as well. In 
this study we examined whether treatment with HDACi affects JCPyV viruria. We analyzed 
randomized, blinded patient samples from the CLEAR cohort (clinical trial #NCT01680094), in 
which HIV-positive cART-adherent patients were treated orally with HDACi panobinostat for eight 
weeks. We detected JCPyV DNA in the urine of 4/15 (27%) of patients, and NCCR sequencing 
confirmed homology to the archetype JCPyV. We demonstrate that 3 out of 4 (75%) of patients 
had a statistically significant increase in JCPyV genome copies during treatment than at baseline 
measurements. This increase was abrogated in post-treatment follow up urine samples. Taken 
together, these findings suggest that HDACi may increase JCPyV viruria in patients. This study 
emphasizes the need to understand the effects of these global HDACi on other latent viruses to 





Combination antiretroviral therapy (cART) controls replication of HIV-1 by affecting 
different stages of the viral life cycle (1). The use of cART has led to a prolongation of the lifespan 
of HIV-positive individuals and an improvement in quality of life, transforming HIV infection from 
a life-threatening disease into a chronic infectious diseases (2, 3). Despite the efficacy of cART, 
it is unable to completely eliminate infected cells and treatment is lifelong. 
One of the main obstacles to curative HIV treatment is the existence of proviral DNA in 
memory CD4+ T cells. These cells present a major difficulty for HIV eradication because once 
reactivated, these latently infected cells are a potential source of new viruses (4). Although HIV 
integrates into the host DNA it cannot express itself significantly, and in the absence of adequate 
stimuli latent reservoirs are stable and resistant to multiple treatment regimens (5). Recently, 
studies have identified drugs which are able to reverse latency without activating T cells and 
causing the production of new virions (6). This new strategy combines these latency reversal 
agents (LRA) with cART to activate production of virus by latently infected cells and eliminate 
them with cART. LRA include disulfiram and histone deacetylase inhibitors (HDACi) such as 
vorinostat (suberoylanilide hydroxamic acid or SAHA) or panobinostat (LBH589, FarydakTM) (7,8). 
The role of HDAC is to remodel chromatin leading to a transcriptionally repressed state. HDACi 
impede that process, causing the chromatin to remain in a conformationally active state (9). 
The ability of HDACi to reactivate HIV suggests the possibility of reactivation of other latent 
viruses as well. One virus in which reactivation is a concern is human polyomavirus JC (JCPyV), 
etiological agent of the demyelinating disease, progressive multifocal leukoencephalopathy 
(PML). PML was originally recognized as a rare complication of hematological malignancies or 
systemic inflammatory disorders, however, a dramatic 50-fold increase in the incidence in the last 
30 years occurred as a result of the acquired immunodeficiency syndrome (AIDS) epidemic (10). 
AIDS is the most frequent condition associated with PML (11), with approximately 6% of patients 
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developing AIDS related PML (12). Recently, studies have demonstrated that HDACi increase 
Mad-1 JCPyV replication in vitro, but lack of an animal model prevents studies in vivo  (13). Due 
to the relationship between PML and AIDS, determining if unintentional reactivation of JCPyV 
occurs with LRAs is a crucial determinant for risk-stratification in future treatments.  
To our knowledge, this is the first study to examine whether treatment with HDACi affects 
JCPyV viruria. We detected JCPyV DNA in the urine of 4 of 15 (27%) of patients, and NCCR 
sequencing confirmed homology to the archetype JCPyV. We demonstrate that patients treated 
with panobinostat had higher detectable amounts of JCPyV viruria than their baseline urine. This 
increase was abrogated in post-treatment follow up urine samples. Taken together, these findings 
suggest that HDACi may increase JCPyV viruria in patients. Additional studies are warranted on 
the effects of LRAs on latent human viruses to minimize the risk of unintentional reactivation.   
 
Results 
Study design and participants 
Fifteen patients were enrolled in the CLEAR cohort and all completed the panobinostat 
dosing regimen (Fig. 1). All participants were white males with a median age of 47 years (range: 
28-53). The median time since HIV diagnosis was 81.4 months (range: 33.4-340) and median 
days from diagnosis to cART initiation was 540 (range: 0-6574). Patients were on cART a median 
of 43.4 months (range: 30.5-191.7) and had a median of 38 months (range: 26.3-169.6) with HIV 
RNA <50 copies per mL. Patients had a median nadir CD4 350 cells per µL (range: 130-710) and 
median baseline CD4 count of 935 cells per µL (range: 615-1990). Patients received oral 
panobinostat (20 mg) three times per week for 8 weeks while continuing cART. This regimen was 
based on clinical safety and preclinical testing of the effect of panobinostat on HIV production in 
latently infected cells Urine samples were collected at before treatment (baseline), on-
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panobinostat during the first (early panobinostat) and third (late panobinostat) treatment cycle, 
and four weeks post-panobinostat (follow up) (Fig. 2). CSF samples were taken at baseline and 
late panobinostat.  
 
JCPyV detected in urine of panobinostat-treated patients 
DNA was extracted from 1 mL of urine or 100 µL of CSF and conventional PCR of the 
JCPyV non-coding regulatory region (NCCR) and major viral capsid protein VP1 genes were 
performed and visualized on a 2% agarose gel. Four out of fifteen (27%) patient’s urine tested 
positive for archetype JCPyV, and all four were positive at all time points measured (Table 1). 
JCPyV DNA was not detected in any of the CSF samples. All urine and CSF samples were 
positive for GAPDH gene. Positive urine samples underwent gel extraction and NCCR 
sequencing to compare baseline and follow up samples. Sequencing results showed no 
difference in NCCR gene between baseline and follow up samples, and NCCR sequences aligned 
with archetype JCPyV (GenBank accession number M35834) (Fig. 3).  
 
Panobinostat increases archetype JCPyV viruria in panobinostat-treated patients 
JCPyV positive urine samples underwent quantitative analysis of JCPyV genome copies 
by qPCR using primers and probes specific for early viral protein T antigen (TAg) and VP1, 
normalized to GAPDH. Three out of four (75%) patients showed a statistically significant increase 
in JCPyV genome copies per mL of urine during late panobinostat treatment compared to 
baseline.  P values are as follows: PID 7 VP1 (p = 0.0077), PID 10 VP1 (p = 0.0198, p = 0.0140), 
PID 12 TAg and VP1 (p <0.0001, p<0.0001), PID 17 TAg and VP1 (p = 0.0155, p = 0.0149). This 




Histone deacetylase inhibitors make up the majority of LRAs in clinical trials (14). 
Therefore, understanding the effect of LRAs on latent viruses is crucial before implementing 
treatment regimens involving these drugs, especially in patients who are immunocompromised. 
JCPyV is of significance since 80% of PML cases occur in the HIV population (10). In this study, 
we examined JCPyV viruria in panobinostat-treated HIV-positive individuals on uninterrupted 
cART.  
We demonstrate that 4/15 (27%) of the panobinostat-treated patients were positive by 
urine at all time points tested. JCPyV viruria varies depending on location, population, immune 
status, and ethnicity and can be intermittent with periods of little to no excretion (15, 16). In healthy 
populations, it’s estimated that approximately 15-30% of individuals shed JCPyV compared to 
approximately 20-45% of HIV-infected individuals (17, 18). Our results are consistent with this 
data. JCPyV is not detected in the CSF until the onset of PML (16) and JCPyV positive CSF is 
used to confirm a PML diagnosis (19). None of the patients treated with panobinostat developed 
PML, therefore we did not expect to detect any JCPyV in the CSF.  
JCPyV positive urine samples NCCR sequence aligned with archetype JCPyV sequence, 
which was expected as archetype JCPyV is excreted in the urine and is latent in the kidneys, 
whereas rearranged JCPyV is detected in the brain or CSF (19, 20). However, we did not detect 
any changes in NCCR sequence between baseline and follow up. This could be due to the nature 
of double-stranded DNA viruses, which are more structurally stable biomolecules and utilize host 
DNA replication machinery that have a low error rate, causing DNA viruses to mutate much slower 
than their RNA counterparts. Alternatively, it could be relatively the short treatment cycle of 
panobinostat (8 weeks), as JCPyV is a lifelong infection that presumably takes many years and 
specific immune-conditions to accumulate pathogenic mutations. Studies performed in our 
laboratory with cells transformed with SV40 TAg to drive JCPyV replication did not induce 
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rearrangements in archetype JCPyV until day 645 after infection. The effect on JCPyV NCCR 
sequence in longer HDACi treatment cycles should be assessed for pathogenic mutations.   
 Lastly, we demonstrate an increase in JCPyV viruria during late panobinostat treatment 
(third treatment cycle) compared to corresponding baseline samples. This increase is significant 
as the current model of PML pathogenesis implicates increased viral replication in the absence 
of a sufficient immune response as the source for the emergence of pathogenic viral variants. 
Studies have shown that the rearranged viruses within a PML patient are derived from the 
archetype virus detected in the kidney of the same patient and that the rearranged virus exists as 
a population of quasispecies in the PML brain, with up to 20 subtypes in one individual (19). These 
support the hypothesis that the archetype virus undergoes rearrangements in the host, further 
highlighting the importance of host immunity in PML pathogenesis. More studies are needed to 




To our knowledge, this is the first study to examine archetype JCPyV viruria in HIV-positive 
individuals treated with an HDACi. We detected JCPyV in the urine of four out of fifteen (27%) 
patients, who shed JCPyV at all time points tested, however JCPyV was not detected in any CSF 
samples. JCPyV NCCR sequencing showed no difference between the initial and final urine 
samples and sequences aligned to the archetype JCPyV, as expected. We also demonstrated 
statistically significant increase in JCPyV genome copies in three out of four (75%) JCPyV PCR 
positive urine at late panobinostat treatment when compared to baseline measurements, and this 
increase was abrogated at follow up. This study emphasizes the need to study the effects of these 
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global HDACi on other latent viruses to improve risk stratification and minimize complications for 
LRA treatments. 
 
Materials and Methods 
Study design and participants 
The phase 1/2 clinical trial was conducted at the Aarhus University Hospital in Denmark 
between October 1, 2012 and January 16, 2014 (CLEAR cohort clinical trial # NCT01680094). 
HIV-infected adults taking antiretroviral therapy with virological suppression (<50 copies per mL) 
for at least two years and CD4 counts above 500 cells per µL were enrolled. Exclusion criteria 
were co-infection with hepatitis B or C viruses, clinically significant cardiac disease including QTc 
prolongation, and current use of a protease inhibitor (due to drug interactions). Patients provided 
written and informed consent before any study procedures, and ethics committee approval was 
obtained. Patients received oral panobinostat (20 mg) three times per week (Mondays, 
Wednesdays, Fridays) every other week for 8 weeks while maintaining combination antiretroviral 
treatment. Patients had 13 follow up visits during treatment and samples were taken roughly eight 
hours after panobinostat dose. Randomized blinded patient urine and CSF samples were 
provided for this study.  
 
PCR amplification and sequence analysis 
JCPyV NCCR and VP1 genes were amplified using 2 µL of template DNA and primers 
JRR-25 and JRR-28 or JLP-15 and JLP-16 as described previously (21). PCR products were 
separated on a 2% agarose gel, visualized with ultraviolet light, NCCR product was purified by 
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QIAquick PCR purification column and sequenced for differences in NCCR. Sequence analysis 
was conducted using Clustal W program.  
 
DNA extraction and quantitative analysis 
Low molecular weight DNA was extracted from 1 mL of urine as previously described (21). 
Two µL of JCPyV DNA template, 10 pmol each of forward and reverse primers, and probe specific 
for JCPyV TAg and for VP1 genes in a final reaction volume of 20 µL were amplified as previously 
published by our group and normalized to GAPDH (22). qPCR was conducted using a Bio-Rad 
iCycler iQ™ Multicolor Real-Time PCR Detection System. Analysis was conducted via Bio-Rad 
iCycler iQ™ Multicolor Real-Time PCR Optical System Software Version 3.1. Statistical analysis 
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Figure 1. Panobinostat treatment schedule. Patients were treated with 20 mg oral panobinostat 










Table 2. Detection of JCPyV DNA in HIV positive cART adherent patients 








7 + + + + 
10 + + + + 
12 + + + + 
17 + + + + 
1 - - - - 
4 - - - - 
5 - - - - 
6 - - - - 
8 - - - - 
9 - - - - 
14 - - - - 
15 - - - - 
18 - - - - 




Mad-1 CY 7 B 7 F 10 B  10 F 12 B  12 F 17 B 17 F 
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Figure 2. JCPyV NCCR sequencing of JCPyV DNA in HIV positive cART adherent patients 
during panobinostat treatment. Amplification of the NCCR by PCR with JCPyV specific NCCR 
primers JRR-25 and JRR-28 and sequence analysis by Clustal W demonstrate percent identity 
of JCPyV positive patient IDs compared to archetype JCPyV (CY [GenBank #M35834] and Mad-














Figure 3. JCPyV TAg and VP1 gene copies in panobinostat treated HIV positive cART 
adherent patients. One mL of urine was pelleted, washed with PBS, and DNA was extracted. 
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